title: Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection.
abstract: The hypothesis that probiotic administration protects the gut surface and could delay progression of Human Immunodeficiency Virus type1 (HIV-1) infection to the Acquired Immunodeficiency Syndrome (AIDS) was proposed in 1995. Over the last five years, new studies have clarified the significance of HIV-1 infection of the gut associated lymphoid tissue (GALT) for subsequent alterations in the microflora and breakdown of the gut mucosal barrier leading to pathogenesis and development of AIDS. Current studies show that loss of gut CD4+ Th17 cells, which differentiate in response to normal microflora, occurs early in HIV-1 disease. Microbial translocation and suppression of the T regulatory (Treg) cell response is associated with chronic immune activation and inflammation. Combinations of probiotic bacteria which upregulate Treg activation have shown promise in suppressing pro inflammatory immune response in models of autoimmunity including inflammatory bowel disease and provide a rationale for use of probiotics in HIV-1/AIDS. Disturbance of the microbiota early in HIV-1 infection leads to greater dominance of potential pathogens, reducing levels of bifidobacteria and lactobacillus species and increasing mucosal inflammation. The interaction of chronic or recurrent infections, and immune activation contributes to nutritional deficiencies that have lasting consequences especially in the HIV-1 infected child. While effective anti-retroviral therapy (ART) has enhanced survival, wasting is still an independent predictor of survival and a major presenting symptom. Congenital exposure to HIV-1 is a risk factor for growth delay in both infected and non-infected infants. Nutritional intervention after 6 months of age appears to be largely ineffective. A meta analysis of randomized, controlled clinical trials of infant formulae supplemented with Bifidobacterium lactis showed that weight gain was significantly greater in infants who received B. lactis compared to formula alone. Pilot studies have shown that probiotic bacteria given as a supplement have improved growth and protected against loss of CD4+ T cells. The recognition that normal bacterial flora prime neonatal immune response and that abnormal flora have a profound impact on metabolism has generated insight into potential mechanisms of gut dysfunction in many settings including HIV-1 infection. As discussed here, current and emerging studies support the concept that probiotic bacteria can provide specific benefit in HIV-1 infection. Probiotic bacteria have proven active against bacterial vaginosis in HIV-1 positive women and have enhanced growth in infants with congenital HIV-1 infection. Probiotic bacteria may stabilize CD4+ T cell numbers in HIV-1 infected children and are likely to have protective effects against inflammation and chronic immune activation of the gastrointestinal immune system.
authors.affiliation: Weill-Cornell Cellular Immunology Laboratory, Division of Hematology/Oncology, Host Defenses Program, Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10065, USA.
authors.forename: Susanna
authors.initials: S
authors.lastname: Cunningham-Rundles
authors.forename: Siv
authors.initials: S
authors.lastname: Ahrné
authors.forename: Rosemary
authors.initials: R
authors.lastname: Johann-Liang
authors.forename: Rachel
authors.initials: R
authors.lastname: Abuav
authors.forename: Ann-Margaret
authors.initials: AM
authors.lastname: Dunn-Navarra
authors.forename: Claudia
authors.initials: C
authors.lastname: Grassey
authors.forename: Stig
authors.initials: S
authors.lastname: Bengmark
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Cervia
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000503:physiopathology; D018988:Bacterial Translocation; D001644:Bifidobacterium; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D019587:Dietary Supplements; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy / Q000635:transmission; D019247:HIV Wasting Syndrome / Q000628:therapy; D015497:HIV-1; D006801:Humans; D007223:Infant; D041943:Infant Formula; D018445:Infectious Disease Transmission, Vertical; D007249:Inflammation; D007413:Intestinal Mucosa / Q000276:immunology / Q000382:microbiology; D007778:Lactobacillus; D015201:Meta-Analysis as Topic; D009752:Nutritional Status; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016585:Vaginosis, Bacterial; D015430:Weight Gain